Zabed Mahmud
Edmonton, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Matrix metalloproteinase inhibition protects against junctophilin-2 proteolysis during doxorubicin-induced cardiotoxicity.
Journal: British journal of pharmacology
Published: November 25, 2024
MMP-2 inhibition attenuates ER stress-mediated cell death during myocardial ischemia-reperfusion injury by preserving IRE1α.
Journal: Journal of molecular and cellular cardiology
Published: January 19, 2024
Matrix metalloproteinase-2 proteolyzes mitofusin-2 and impairs mitochondrial function during myocardial ischemia-reperfusion injury.
Journal: Basic research in cardiology
Published: December 23, 2022
MMP inhibition attenuates hypertensive eccentric cardiac hypertrophy and dysfunction by preserving troponin I and dystrophin.
Journal: Biochemical pharmacology
Published: May 21, 2021
Dilated Cardiomyopathy Mutations and Phosphorylation disrupt the Active Orientation of Cardiac Troponin C.
Journal: Journal of molecular biology
Published: February 18, 2021
Junctophilin-2 is a target of matrix metalloproteinase-2 in myocardial ischemia-reperfusion injury.
Journal: Basic research in cardiology
Published: April 18, 2019
Myocardial MMP-2 contributes to SERCA2a proteolysis during cardiac ischaemia-reperfusion injury.
Journal: Cardiovascular research
Published: December 13, 2018
Structure and proteolytic susceptibility of the inhibitory C-terminal tail of cardiac troponin I.
Journal: Biochimica et biophysica acta. General subjects
Published: September 14, 2018
Showing 1-9 of 9
Last Updated: 09/26/2026